Skip to main content
Top
Published in: Clinical Research in Cardiology 1/2017

01-01-2017 | Original Paper

Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation

Authors: Melanie Gunawardene, S. Willems, B. Schäffer, J. Moser, R. Ö. Akbulak, M. Jularic, C. Eickholt, J. Nührich, C. Meyer, P. Kuklik, S. Sehner, V. Czerner, B. A. Hoffmann

Published in: Clinical Research in Cardiology | Issue 1/2017

Login to get access

Abstract

Background

The use of non-vitamin K antagonists (NOACs), uninterrupted (uVKA) and interrupted vitamin K antagonists (iVKA) are common periprocedural oral anticoagulation (OAC) strategies for atrial fibrillation (AF) ablation. Comparative data on complication rates resulting from OAC strategies for solely persistent AF (persAF) undergoing ablation are sparse. Thus, we sought to determine the impact of these OAC strategies on complication rates among patients with persAF undergoing catheter ablation.

Methods

Consecutive patients undergoing persAF ablation were included. Depending on preprocedural OAC, three groups were defined: (1) NOACs (paused 48 h preablation), (2) uVKA, and (3) iVKA with heparin bridging. A combined complication endpoint (CCE) composed of bleeding and thromboembolic events was analyzed.

Results

Between 2011 and 2014, 1440 persAF ablation procedures were performed in 1092 patients. NOACs were given in 441 procedures (31 %; rivaroxaban 57 %, dabigatran 33 %, and apixaban 10 %), uVKA in 488 (34 %), and iVKA in 511 (35 %). Adjusted CCE rates were 5.5 % [95 % confidence interval (CI) (3.1–7.8)] in group 1 (NOACs), 7.5 % [95 % CI (5.0–10.1)] in group 2 (uVKA), and 9.9 % [95 % CI (6.6–13.2)] in group 3. Compared to group 1, the combined complication risk was almost twice as high in group 3 [odd’s ratio (OR) 1.9, 95 % CI (1.0–3.7), p = 0.049)]. The major complication rate was low (0.9 %). Bleeding complications, driven by minor groin complications, are more frequent than thromboembolic events (n = 112 vs. 1, p < 0.0001).

Conclusions

Patients undergoing persAF ablation with iVKA anticoagulation have an increased risk of complications compared to NOACs. Major complications, such as thromboembolic events, are generally rare and are exceeded by minor bleedings.
Literature
1.
go back to reference Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A et al (2012) Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications evidence from a meta-analysis. Circ Arrhythmia Electrophysiol 5(2):302–311CrossRef Santangeli P, Di Biase L, Horton R, Burkhardt JD, Sanchez J, Al-Ahmad A et al (2012) Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications evidence from a meta-analysis. Circ Arrhythmia Electrophysiol 5(2):302–311CrossRef
2.
go back to reference Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H (2015) Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol 187:426–429CrossRefPubMed Nairooz R, Sardar P, Payne J, Aronow WS, Paydak H (2015) Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol 187:426–429CrossRefPubMed
3.
go back to reference Weitz JI, Healey JS, Skanes AC, Verma A (2014) Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation 129(16):1688–1694CrossRefPubMed Weitz JI, Healey JS, Skanes AC, Verma A (2014) Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation. Circulation 129(16):1688–1694CrossRefPubMed
4.
go back to reference Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M et al (2013) Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythmia Electrophysiol 6(3):460–464CrossRef Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M et al (2013) Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythmia Electrophysiol 6(3):460–464CrossRef
5.
go back to reference Kim J-S, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H et al (2013) Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 10(4):483–489CrossRefPubMed Kim J-S, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H et al (2013) Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 10(4):483–489CrossRefPubMed
6.
go back to reference Kaess B, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V et al (2015) Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 115(1):47–51CrossRefPubMed Kaess B, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V et al (2015) Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 115(1):47–51CrossRefPubMed
7.
go back to reference Garg J, Chaudhary R, Krishnamoorthy P, Shah N, Natale A, Bozorgnia B (2016) Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: a metaanalysis of 1362 patients. Int J Cardiol 203:906–908CrossRefPubMed Garg J, Chaudhary R, Krishnamoorthy P, Shah N, Natale A, Bozorgnia B (2016) Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: a metaanalysis of 1362 patients. Int J Cardiol 203:906–908CrossRefPubMed
8.
go back to reference Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H et al (2015) Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. Intern Med 54(10):1167–1173CrossRefPubMed Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H et al (2015) Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. Intern Med 54(10):1167–1173CrossRefPubMed
9.
go back to reference Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P et al (2014) Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 63(10):982–988CrossRefPubMed Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P et al (2014) Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 63(10):982–988CrossRefPubMed
10.
go back to reference Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 103(3):173–182CrossRefPubMed Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 103(3):173–182CrossRefPubMed
11.
go back to reference Di Biase L, Lakkireddy D, Trivedi C, Denke T, Martinek M, Mohanty S (2015) Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Hear Rhythm 12:1162–1168CrossRef Di Biase L, Lakkireddy D, Trivedi C, Denke T, Martinek M, Mohanty S (2015) Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Hear Rhythm 12:1162–1168CrossRef
12.
go back to reference Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA (2014) Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace 16(10):1443–1449CrossRefPubMedCentralPubMed Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA (2014) Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban. Europace 16(10):1443–1449CrossRefPubMedCentralPubMed
13.
go back to reference Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC (2012) Periprocedural heparin bridging in patients receiving Vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126(13):1630–1639CrossRefPubMed Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC (2012) Periprocedural heparin bridging in patients receiving Vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126(13):1630–1639CrossRefPubMed
14.
go back to reference Kim J-S, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T et al (2013) The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythmia Electrophysiol 6(2):302–309CrossRef Kim J-S, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T et al (2013) The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythmia Electrophysiol 6(2):302–309CrossRef
15.
go back to reference Vogler J, Willems S, Sultan A, Schreiber D, Lüker J, Servatius H et al (2015) Pulmonary vein isolation versus defragmentation. J Am Coll Cardiol 66(24):2743–2752CrossRefPubMed Vogler J, Willems S, Sultan A, Schreiber D, Lüker J, Servatius H et al (2015) Pulmonary vein isolation versus defragmentation. J Am Coll Cardiol 66(24):2743–2752CrossRefPubMed
16.
go back to reference Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA et al (2015) Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol 8(2):308–317CrossRefPubMed Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA et al (2015) Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol 8(2):308–317CrossRefPubMed
17.
go back to reference Hoffmann BA, Kuck K-H, Andresen D, Spitzer SG, Hoffmann E, Schumacher B et al (2014) Impact of structural heart disease on the acute complication rate in atrial fibrillation ablation: results from the German Ablation Registry. J Cardiovasc Electrophysiol 25(3):242–249CrossRefPubMed Hoffmann BA, Kuck K-H, Andresen D, Spitzer SG, Hoffmann E, Schumacher B et al (2014) Impact of structural heart disease on the acute complication rate in atrial fibrillation ablation: results from the German Ablation Registry. J Cardiovasc Electrophysiol 25(3):242–249CrossRefPubMed
18.
go back to reference Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM (2015) Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. Am J Med 128(6):654.e1–654.e10CrossRef Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM (2015) Differences in anticoagulant therapy prescription in patients with paroxysmal versus persistent atrial fibrillation. Am J Med 128(6):654.e1–654.e10CrossRef
19.
go back to reference Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al (2013) European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15(5):625–651CrossRefPubMed Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al (2013) European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15(5):625–651CrossRefPubMed
20.
go back to reference Salukhe TV, Willems S, Drewitz I, Steven D, Hoffmann BA, Heitmann K et al (2012) Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation. Europace 14(3):325–330CrossRefPubMed Salukhe TV, Willems S, Drewitz I, Steven D, Hoffmann BA, Heitmann K et al (2012) Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation. Europace 14(3):325–330CrossRefPubMed
21.
go back to reference Lankveld T, Zeemering S, Scherr D, Kuklik P, Hoffmann BA, Willems S et al (2016) Atrial fibrillation complexity parameters derived from surface ECGs predict procedural outcome and long-term follow-up of stepwise catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 9(2):e003354CrossRefPubMed Lankveld T, Zeemering S, Scherr D, Kuklik P, Hoffmann BA, Willems S et al (2016) Atrial fibrillation complexity parameters derived from surface ECGs predict procedural outcome and long-term follow-up of stepwise catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 9(2):e003354CrossRefPubMed
22.
go back to reference Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen S-A et al (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm 9(4):632–696CrossRefPubMed Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen S-A et al (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm 9(4):632–696CrossRefPubMed
23.
go back to reference Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R et al (2014) Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin in preventing thromboembolism in atrial fibrillation (AF) patient. Circulation 129(25):2638–2644CrossRefPubMed Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R et al (2014) Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of Coumadin in preventing thromboembolism in atrial fibrillation (AF) patient. Circulation 129(25):2638–2644CrossRefPubMed
24.
go back to reference Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS et al (2010) Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing Clin Electrophysiol 33:146–152CrossRefPubMed Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS et al (2010) Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing Clin Electrophysiol 33:146–152CrossRefPubMed
25.
go back to reference Nademanee K, Amnueypol M, Lee F, Drew CM, Suwannasri W, Schwab MC et al (2015) Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm 12(1):44–51CrossRefPubMed Nademanee K, Amnueypol M, Lee F, Drew CM, Suwannasri W, Schwab MC et al (2015) Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm 12(1):44–51CrossRefPubMed
26.
go back to reference Spragg DD, Dalal D, Cheema A, Scherr D, Chilukuri K, Cheng A et al (2008) Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 19(6):627–631CrossRefPubMed Spragg DD, Dalal D, Cheema A, Scherr D, Chilukuri K, Cheng A et al (2008) Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 19(6):627–631CrossRefPubMed
27.
go back to reference Nührich JM, Kuck KH, Andresen D, Steven D, Spitzer SG, Hoffmann E et al (2015) Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clin Res Cardiol 104(6):463–470CrossRefPubMed Nührich JM, Kuck KH, Andresen D, Steven D, Spitzer SG, Hoffmann E et al (2015) Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clin Res Cardiol 104(6):463–470CrossRefPubMed
28.
go back to reference Kornej J, Kosiuk J, Hindricks G, Arya A, Sommer P, Rolf S et al (2015) Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Clin Res Cardiol 104(7):603–610CrossRefPubMed Kornej J, Kosiuk J, Hindricks G, Arya A, Sommer P, Rolf S et al (2015) Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Clin Res Cardiol 104(7):603–610CrossRefPubMed
29.
go back to reference Rillig A, Lin T, Plesman J, Heeger C-H, Lemes C, Metzner A et al (2016) Apixaban, rivaroxaban and dabigatran in patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol 27(2):147–153CrossRefPubMed Rillig A, Lin T, Plesman J, Heeger C-H, Lemes C, Metzner A et al (2016) Apixaban, rivaroxaban and dabigatran in patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol 27(2):147–153CrossRefPubMed
30.
go back to reference Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W et al (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467–1507CrossRefPubMed Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W et al (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17(10):1467–1507CrossRefPubMed
31.
go back to reference Nagao T, Inden Y, Yanagisawa S, Kato H, Ishikawa S, Okumura S et al (2015) Differences in the activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart Rhythm 12(9):1972–1978CrossRefPubMed Nagao T, Inden Y, Yanagisawa S, Kato H, Ishikawa S, Okumura S et al (2015) Differences in the activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Heart Rhythm 12(9):1972–1978CrossRefPubMed
32.
go back to reference Bin Abdulhak A, Kennedy K, Gupta S, Giocondo M, Ramza B, Wimmer A (2015) Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study. J Cardiovasc Electrophysiol 44(2):91–96CrossRef Bin Abdulhak A, Kennedy K, Gupta S, Giocondo M, Ramza B, Wimmer A (2015) Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study. J Cardiovasc Electrophysiol 44(2):91–96CrossRef
Metadata
Title
Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation
Authors
Melanie Gunawardene
S. Willems
B. Schäffer
J. Moser
R. Ö. Akbulak
M. Jularic
C. Eickholt
J. Nührich
C. Meyer
P. Kuklik
S. Sehner
V. Czerner
B. A. Hoffmann
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 1/2017
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-016-1021-x

Other articles of this Issue 1/2017

Clinical Research in Cardiology 1/2017 Go to the issue